Qiu Yingshan, Lo Jason C K, Kwok Kerry C W, Mason A James, Lam Jenny K W
Department of Pharmacology and Pharmacy, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong, Hong Kong.
Institute of Pharmaceutical Science, School of Cancer & Pharmaceutical Science, King's College London, London, United Kingdom.
Nucleic Acid Ther. 2021 Jun;31(3):220-228. doi: 10.1089/nat.2020.0855. Epub 2020 Apr 29.
A safe and effective delivery system is considered a key to the success of nucleic acid therapeutics. It has been reported that pulmonary surfactants or their components could facilitate the uptake of small interfering RNA (siRNA) into the lung epithelial cells. Previously, our group investigated the use of KL4 peptide, a synthetic cationic peptide that simulates the structural properties of surfactant protein B (SP-B), as siRNA delivery vector. Although KL4 peptide exhibits good siRNA transfection efficiency on lung epithelial cells, its therapeutic potential is limited by its poor aqueous solubility due to the presence of a high proportion of hydrophobic leucine residues. In this study, we aim to address the solubility issue, designing five different modified peptides by replacing the hydrophobic leucine with alanine or valine, and assess their potential as siRNA delivery vectors. While the modified peptides retain the overall cationic property, their siRNA binding is also affected and their transfection efficiency is inferior to the parent KL4 peptide. A closer examination of the conformation of these peptides by circular dichroism shows that substitution of leucine residues leads to the change of the secondary structure from α-helical content to either β-sheet or more disordered, β-turn conformations. Relatively conservative amino acid substitutions, in terms of hydrophobicity bulk, lead to substantial conformational alteration, heavily impacting siRNA binding and release, cellular uptake, and transfection efficiency. Although the peptide modification strategy employed in this study was unsuccessful in developing an improved version of KL4 peptide for siRNA delivery, it highlights the importance of the α-helical conformation for efficient siRNA transfection, providing useful insights for future development of peptide-based RNA delivery system.
一种安全有效的递送系统被认为是核酸治疗成功的关键。据报道,肺表面活性剂或其成分可促进小干扰RNA(siRNA)进入肺上皮细胞。此前,我们小组研究了KL4肽的用途,KL4肽是一种模拟表面活性蛋白B(SP-B)结构特性的合成阳离子肽,作为siRNA递送载体。尽管KL4肽在肺上皮细胞上表现出良好的siRNA转染效率,但其治疗潜力受到其较差的水溶性限制,这是由于存在高比例的疏水性亮氨酸残基。在本研究中,我们旨在解决溶解性问题,通过用丙氨酸或缬氨酸取代疏水性亮氨酸设计了五种不同的修饰肽,并评估它们作为siRNA递送载体的潜力。虽然修饰后的肽保留了整体阳离子性质,但它们与siRNA的结合也受到影响,并且它们的转染效率低于亲本KL4肽。通过圆二色性对这些肽的构象进行更仔细的研究表明,亮氨酸残基的取代导致二级结构从α-螺旋含量转变为β-折叠或更无序的β-转角构象。就疏水性体积而言,相对保守的氨基酸取代导致构象发生实质性改变,严重影响siRNA的结合和释放、细胞摄取以及转染效率。尽管本研究中采用的肽修饰策略未能成功开发出用于siRNA递送的改良版KL4肽,但它突出了α-螺旋构象对于有效siRNA转染的重要性,为基于肽的RNA递送系统的未来发展提供了有用的见解。